This story originally ran on Feb. 18.
Japanese research foundation Riken has chosen Genedata's Expressionist software to support biomarker research into cancer, the company said this week.
Riken is using proteomics and mass spectrometry to identify biomarkers for the development of serum-based diagnostics. In a statement, Koki Ueda, a project leader at the Laboratory for Biomarker Development at Riken, said that its proteomics facility generates "huge amounts" of mass spec data. Data analysis has been a "major bottleneck" — particularly for clinical proteomics, where there is a need to quantitatively analyze as many clinical samples as possible due to individual variations.
Genedata Expressionist, Ueda said, "is the only solution we found that can meet our high-throughput needs."
Riken's biomarker development group is using the Refiner MS and Analyst modules from the Genedata Expressionist system for high-throughput LC-MS proteomics data processing and analysis.